[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353419-105":59,"doc-detail-353419-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrating-a-see-and-treat-approach-with-opportunistic-hpv-dna-based-cervical-cancer-screening-in-india-a-retrospective-crosssectional-study","Integrating a “see-and-treat” approach with opportunistic human papilloma virus deoxyribonucleic acid (HPV DNA) based cervical cancer screening in India - a retrospective crosssectional study","","India lacks an organized national cervical cancer screening program, and evidence on decentralized implementation of WHO-recommended hrHPV DNA testing remains limited. This retrospective cross-sectional study evaluated opportunistic hrHPV DNA screening across 20 Indian states, focusing on prevalence, genotype distribution, self-testing acceptance, and the diagnostic performance of a community-based “see-and-treat” approach. Outcomes also assessed treatment compliance and the clinical viability of linkage-to-care to support timely management in decentralized settings.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrating-a-see-and-treat-approach-with-opportunistic-hpv-dna-based-cervical-cancer-screening-in-india-a-retrospective-crosssectional-study/353419/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrating-a-see-and-treat-approach-with-opportunistic-hpv-dna-based-cervical-cancer-screening-in-india-a-retrospective-crosssectional-study/353419.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why was this study conducted in India?","Question",{"text":112,"@type":113},"India does not have an organized national cervical cancer screening program, and large-scale evidence for decentralized “see-and-treat” implementation of WHO-recommended HPV DNA testing was limited.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What approach did the study evaluate?",{"text":117,"@type":113},"The study assessed opportunistic high-risk HPV DNA screening and the diagnostic performance of a community-based “see-and-treat” approach, including prevalence, genotype distribution, and self-testing acceptance.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the study conclusions regarding implementation?",{"text":121,"@type":113},"A decentralized “see-and-treat” hrHPV DNA screening model achieved high diagnostic accuracy, but improved digital linkage-to-care was needed to overcome treatment compliance barriers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353419,1790941182,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Original Research AJOG Global Reports  \nIntegrating a “see-and-treat” approach with   \nopportunistic human papilloma virus deoxyribonucleic acid (HPV DNA) based cervical cancer screening in India: a retrospective crosssectional study  \nSripriya Rao, BE; Mayank Chhabra, MPH, MBA; Jagadish Kudkuli, PhD; Milan Toraskar, MBA;  \nAswathy G. Nath, MS, DNB; Devu Prakash, MBBS; Shweta Srivastava, MBA; Wahengbam Imo Singh, MSW;  \nMalini Chandrasekharan, MBBS, DO; Kunal Oswal, MPH; Jaganjeet Randhawa, BDS, MPH; Venkataramanan Ramachandran, PhD  \nBACKGROUND: India lacks an organized national cervical cancer screening program, and while the World Health Organization (WHO) recommends human papillomavirus (HPV) deoxyribonucleic acid (DNA) testing as the primary modality, large-scale evidence on implementation via decentralized treatment pathways in India is limited. We evaluated the effectiveness of opportunistic high-risk HPV (hrHPV) DNA screening, assessing prevalence, genotype distribution, self-testing acceptance, and the diagnostic performance of a community-based “see-and-treat”approach.  \nOBJECTIVE: To evaluate the prevalence and genotype distribution of hrHPV and assess the diagnostic accuracy, treatment compliance, and clinical viability of a decentralized “see-and-treat” approach within a large-scale opportunistic screening program across 20 Indian states.  \nFrom the Department of Early Detection and Women Wellness, Karkinos Healthcare, Mumbai, India (Rao, Chhabra, Toraskar, Chanderashekharan, Oswal, Randhawa); Distributed Cancer Care Network, Karkinos Healthcare, Mumbai, India (Rao); Advanced Molecular Diagnostics Laboratory, Karkinos Healthcare, Ernakulam, India (Kudkuli); Department of Medical Affairs, Distributed Cancer Care Network, Karkinos Healthcare, Ernakulam, India (Nath); Department of Early Detection and Women Wellness, Karkinos Healthcare, Ernakulam, India (Prakash); Department of Early Detection and Women Wellness, Karkinos Healthcare, Bengaluru, India (Srivastava); Department of Early Detection and Women Wellness, Karkinos Manipur Cancer Institute and Research Centre, Karkinos Healthcare North East, Imphal, Manipur, India (Singh); Karkinos Healthcare, Mumbai, India (Ramachandran) Condensation: A decentralized “see-and-treat” hrHPV DNA screening model in India achieves high diagnostic accuracy but requires improved digital linkage-to-care to overcome treatment compliance barriers.  \nEthics statement and informed consent: Our study protocols for immediate management were based on the established “see-and-treat” work of the late Dr. Rengaswamy Sankaranarayanan. Participants were provided with speciﬁc informed written consent for these procedures before undergoing colposcopy and treatment. The rationale was to ensure timely management and minimize loss to follow-up in settings, where returning for multiple visits is difﬁcult. The study was conducted in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. Formal ethical approval was granted by the Karkinos Healthcare Independent Ethics Committee (KH-IEC) with a Protocol No. KH-IEC/04/2025 . This research involved analysis of deidentiﬁed clinical data collected during routine public health screening initiatives within the study period. The study entailed minimal or no risk to participants. Throughout the study, rigorous procedures were followed to ensure the protection of participant privacy and conﬁdentiality. In accordance with the committee ’s resolution, the substantial contributions of the late Dr. Rengaswamy Sankaranarayanan (formerly coinvestigator) have been formally acknowledged in the manuscript rather than through authorship.  \nData availability: Deidentiﬁed participant data that underlie the results reported in this paper will be made available to others for the purpose of further research and meta-analysis. The study protocol and statistical analysis plan will be made available. These data will be available with public","cbCaio9RG0jyK5KX","https://ap.wps.com/l/cbCaio9RG0jyK5KX","pdf",1076428,12,"English","# Background\n# Objective\n# Study Design\n## Ethics and Informed Consent\n## Data Availability\n## Reporting and Compliance\n# Funding and Conflicts of Interest\n# Corresponding Author","[{\"question\":\"Why was this study conducted in India?\",\"answer\":\"India does not have an organized national cervical cancer screening program, and large-scale evidence for decentralized “see-and-treat” implementation of WHO-recommended HPV DNA testing was limited.\"},{\"question\":\"What approach did the study evaluate?\",\"answer\":\"The study assessed opportunistic high-risk HPV DNA screening and the diagnostic performance of a community-based “see-and-treat” approach, including prevalence, genotype distribution, and self-testing acceptance.\"},{\"question\":\"What were the study conclusions regarding implementation?\",\"answer\":\"A decentralized “see-and-treat” hrHPV DNA screening model achieved high diagnostic accuracy, but improved digital linkage-to-care was needed to overcome treatment compliance barriers.\"}]","Integrating a “see-and-treat” approach with opportunistic human papilloma virus deoxyribonucleic acid (HPV DNA) based cervical cancer screening in India - a retrospective crosssectional study | PDF",1790105258,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee364cf9d30ce8cad76390157f0061bc.webp",983,1320,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/294539633a290bda4dd4a9e6a76f4933.webp",982,1319,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd4b098af0462cd78392f157528bd617.webp",981,1318,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c3ef7ff4f66452d627a431d55d0fd62.webp",980,1316]